Skip to main content
Top
Published in: Supportive Care in Cancer 6/2013

01-06-2013 | Original Article

Home-based zoledronic acid infusion therapy in patients with solid tumours: compliance and patient–nurse satisfaction

Authors: Thierry Lebret, Jean-Loup Mouysset, Alain Lortholary, Claude El Kouri, Laurent Bastit, Meryem Ktiouet, Khemaies Slimane, Xavier Murraciole, Stéphane Guérif

Published in: Supportive Care in Cancer | Issue 6/2013

Login to get access

Abstract

Purpose

This study aimed to explore patient and nurse satisfaction, compliance with best practice, technical feasibility and safety of home infusion of the bisphosphonate zoledronic acid (ZOL).

Methods

This was a prospective 1-year survey of home ZOL therapy (4 mg Zometa®, 15-min i.v., every 3–4 weeks) in patients with bone metastases secondary to a solid malignancy. A physician questionnaire, nurse satisfaction/feasibility questionnaire and patient satisfaction questionnaire were administered at several time-points.

Results

Physician participation rate was 56.5 % (87/154). Physicians enrolled 818 patients visited by 381 predominantly community nurses. Of the 788 case report forms received, 763 met inclusion criteria. Patient characteristics were as follows: median age, 68 years (30–95); M/F, 40/60; ECOG-PS 0 or 1, 78.6 %;and primary tumour site, breast (55.2 %), prostate (28.4 %), lung (7.2 %) or other (9.4 %). Nurse satisfaction rates were high: organisation of home ZOL therapy, 90.9 %; ease of infusion, 96.7 %; patient–nurse relationship, 97.5 %; and relationship with hospital staff, 73 %. Patient satisfaction was also very high (95.3 %). The main reasons were quality of the nurse–patient relationship (57.6 %), less travel/waiting (68.8 %), home environment (52.9 %) and less disruption to daily routine (36.6 %). ZOL therapy was well tolerated, the discontinuation rate due to adverse events (including deaths whether related to diseases progression or not) was 33.6 %. The incidence of osteonecrosis of the jaw was 0.6 % and of fractures, 0.2 %. Practitioner compliance with best practice was 76.7–83.7 % for recommended and/or tolerated dosage, 73 % for dental hygiene checks at inclusion and 48–56 % thereafter, 66 % for pre-infusion hydration, and often undocumented for calcium/vitamin D supplementation.

Conclusions

Home ZOL therapy was well tolerated. Both patient and nurse satisfaction were very high. However, better compliance with best practice should be encouraged.
Appendix
Available only for authorised users
Literature
3.
go back to reference Coleman R, Cook R, Hirsh V, Major P, Lipton A (2011) Zoledronic acid use in cancer patients: more than just supportive care? Cancer 117:11–23PubMedCrossRef Coleman R, Cook R, Hirsh V, Major P, Lipton A (2011) Zoledronic acid use in cancer patients: more than just supportive care? Cancer 117:11–23PubMedCrossRef
4.
go back to reference Berenson JR (2011) Antitumor effects of bisphosphonates: from the laboratory to the clinic. Curr Opin Support Palliat Care 5:233–240PubMed Berenson JR (2011) Antitumor effects of bisphosphonates: from the laboratory to the clinic. Curr Opin Support Palliat Care 5:233–240PubMed
5.
go back to reference Lipton A (2011) Zoledronic acid: multiplicity of use across the cancer continuum. Expert Rev Anticancer Ther 11:999–1012PubMedCrossRef Lipton A (2011) Zoledronic acid: multiplicity of use across the cancer continuum. Expert Rev Anticancer Ther 11:999–1012PubMedCrossRef
6.
go back to reference Wong MH, Stockler MR, Pavlakis N (2012) Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev 2:CD003474PubMed Wong MH, Stockler MR, Pavlakis N (2012) Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev 2:CD003474PubMed
7.
go back to reference Yan T, Yin W, Zhou Q, Zhou L, Jiang Y, Du Y, Shao Z, Lu J (2012) The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials. Eur J Cancer 48:187–195PubMedCrossRef Yan T, Yin W, Zhou Q, Zhou L, Jiang Y, Du Y, Shao Z, Lu J (2012) The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials. Eur J Cancer 48:187–195PubMedCrossRef
8.
go back to reference Chern B, Joseph D, Joshua D, Pittman K, Richardson G, Schou M, Lowe S, Copeman M, De Abreu LR, Lynch K (2004) Bisphosphonate infusions: patient preference, safety and clinic use. Support Care Cancer 12:463–466PubMedCrossRef Chern B, Joseph D, Joshua D, Pittman K, Richardson G, Schou M, Lowe S, Copeman M, De Abreu LR, Lynch K (2004) Bisphosphonate infusions: patient preference, safety and clinic use. Support Care Cancer 12:463–466PubMedCrossRef
9.
go back to reference Marr HK, Stiles CR, Boyar MA, Braun TC, Hagen NA, Janzen C, Whitten LM, Pereira JL (2010) Feasibility of administering zoledronic acid in palliative patients being cared for in the community: results of a pilot study. Curr Oncol 17:69–74PubMedCrossRef Marr HK, Stiles CR, Boyar MA, Braun TC, Hagen NA, Janzen C, Whitten LM, Pereira JL (2010) Feasibility of administering zoledronic acid in palliative patients being cared for in the community: results of a pilot study. Curr Oncol 17:69–74PubMedCrossRef
10.
go back to reference Wardley A, Davidson N, Barrett-Lee P, Hong A, Mansi J, Dodwell D, Murphy R, Mason T, Cameron D (2005) Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 92:1869–1876PubMedCrossRef Wardley A, Davidson N, Barrett-Lee P, Hong A, Mansi J, Dodwell D, Murphy R, Mason T, Cameron D (2005) Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 92:1869–1876PubMedCrossRef
11.
go back to reference Italiano A, Ciais C, Chamorey E, Marcy PY, Largillier R, Ferrero JM, Thyss A (2006) Home infusions of biphosphonate in cancer patients: a prospective study. J Chemother 18:217–220PubMed Italiano A, Ciais C, Chamorey E, Marcy PY, Largillier R, Ferrero JM, Thyss A (2006) Home infusions of biphosphonate in cancer patients: a prospective study. J Chemother 18:217–220PubMed
12.
go back to reference Santangelo A, Testai M, Barbagallo P, Manuele S, Di Stefano A, Tomarchio M, Trizzino G, Musumeci G, Panebianco P, Maugeri D (2006) The use of bisphosphonates in palliative treatment of bone metastases in a terminally ill, oncological elderly population. Arch Gerontol Geriatr 43:187–192PubMedCrossRef Santangelo A, Testai M, Barbagallo P, Manuele S, Di Stefano A, Tomarchio M, Trizzino G, Musumeci G, Panebianco P, Maugeri D (2006) The use of bisphosphonates in palliative treatment of bone metastases in a terminally ill, oncological elderly population. Arch Gerontol Geriatr 43:187–192PubMedCrossRef
13.
go back to reference Tassinari D, Poggi B, Nicoletti S, Fantini M, Tamburini E, Possenti C, Sartori S (2007) Zoledronic acid treatment at home: safety data from an observational prospective trial. J Palliat Med 10:352–358PubMedCrossRef Tassinari D, Poggi B, Nicoletti S, Fantini M, Tamburini E, Possenti C, Sartori S (2007) Zoledronic acid treatment at home: safety data from an observational prospective trial. J Palliat Med 10:352–358PubMedCrossRef
14.
go back to reference Quesnel M (2007) Nurse’s role in the home management of patients with breast cancer and bone metastases. Soins 715:26–28PubMed Quesnel M (2007) Nurse’s role in the home management of patients with breast cancer and bone metastases. Soins 715:26–28PubMed
15.
go back to reference Coleman R, Burkinshaw R, Winter M, Neville-Webbe H, Lester J, Woodward E, Brown J (2011) Zoledronic acid. Expert Opin Drug Saf 10:133–145PubMedCrossRef Coleman R, Burkinshaw R, Winter M, Neville-Webbe H, Lester J, Woodward E, Brown J (2011) Zoledronic acid. Expert Opin Drug Saf 10:133–145PubMedCrossRef
16.
go back to reference Khan AA, Rios LP, Sãndor GK, Khan N, Peters E, Rahman MO, Clokie CM, Dore E, Dubois S (2011) Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons. J Rheumatol 38:1396–1402PubMedCrossRef Khan AA, Rios LP, Sãndor GK, Khan N, Peters E, Rahman MO, Clokie CM, Dore E, Dubois S (2011) Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons. J Rheumatol 38:1396–1402PubMedCrossRef
17.
go back to reference Barrett-Lee P, Bloomfield D, Dougherty L, Harries M, Laing R, Patel H, Walker M (2007) An audit to determine the time taken to administer intravenous bisphosphonate infusions in patients diagnosed with metastatic breast cancer to bone in a hospital setting. Curr Med Res Opin 23:1575–1582PubMedCrossRef Barrett-Lee P, Bloomfield D, Dougherty L, Harries M, Laing R, Patel H, Walker M (2007) An audit to determine the time taken to administer intravenous bisphosphonate infusions in patients diagnosed with metastatic breast cancer to bone in a hospital setting. Curr Med Res Opin 23:1575–1582PubMedCrossRef
18.
go back to reference Jensen BT, Dielenseger P, Drudge-Coates L, Flynn K, Hieronymi S, Erik van Muilekom HA, Pieters R, Voss LB (2012) Taking the lead: sharing best practice in intravenous bisphosphonate use in urological cancers. Eur J Oncol Nurs 16:42–53. doi:10.1016/j.ejon.2011.02.006 PubMedCrossRef Jensen BT, Dielenseger P, Drudge-Coates L, Flynn K, Hieronymi S, Erik van Muilekom HA, Pieters R, Voss LB (2012) Taking the lead: sharing best practice in intravenous bisphosphonate use in urological cancers. Eur J Oncol Nurs 16:42–53. doi:10.​1016/​j.​ejon.​2011.​02.​006 PubMedCrossRef
Metadata
Title
Home-based zoledronic acid infusion therapy in patients with solid tumours: compliance and patient–nurse satisfaction
Authors
Thierry Lebret
Jean-Loup Mouysset
Alain Lortholary
Claude El Kouri
Laurent Bastit
Meryem Ktiouet
Khemaies Slimane
Xavier Murraciole
Stéphane Guérif
Publication date
01-06-2013
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 6/2013
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-012-1705-3

Other articles of this Issue 6/2013

Supportive Care in Cancer 6/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine